Eszopiclone for late-life insomnia

Christina S McCrae1, Amanda Ross1, Ashley Stripling2, Natalie D Dautovich21Department of Clinical and Health Psychology, 2Department of Psychology, University of Florida, Gainesville, Florida, USAAbstract: Insomnia, the most common sleep disturbance in later life, affects 20%–50% of older...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Christina S McCrae, Amanda Ross, Ashley Stripling, Natalie D Dautovich
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2007
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/5302fce03c1e4fbea622ff129aaeed61
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5302fce03c1e4fbea622ff129aaeed61
record_format	dspace
spelling	oai:doaj.org-article:5302fce03c1e4fbea622ff129aaeed612021-12-02T05:07:28ZEszopiclone for late-life insomnia1178-1998https://doaj.org/article/5302fce03c1e4fbea622ff129aaeed612007-10-01T00:00:00Zhttps://www.dovepress.com/eszopiclone-for-late-life-insomnia-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Christina S McCrae1, Amanda Ross1, Ashley Stripling2, Natalie D Dautovich21Department of Clinical and Health Psychology, 2Department of Psychology, University of Florida, Gainesville, Florida, USAAbstract: Insomnia, the most common sleep disturbance in later life, affects 20%–50% of older adults. Eszopiclone, a short-acting nonbenzodiazepine hypnotic agent developed for the treatment of insomnia, has been available in Europe since 1992 and in the US since 2005. Although not yet evaluated for transient insomnia in older adults, eszopiclone has been shown to be safe and efficacious for short-term treatment (2 weeks) of chronic, primary insomnia in older adults (64–91 years). Clinical studies in younger adults (mean = 44 years) have shown eszopiclone can be used for 6–12 months without evidence of problems. Because the oldest participant in these longer-term trials was 69, it not known whether eszopiclone is effective for older adults [particularly the old old (75–84 years) and oldest old (85+)] when used over longer periods. This is unfortunate, because older individuals frequently suffer from chronic insomnia. Cognitive-behavioral therapy for insomnia, which effectively targets the behavioral factors that maintain chronic insomnia, represents an attractive treatment alternative or adjuvant to eszopiclone for older adults. To date, no studies have compared eszopiclone to other hypnotic medications or to nonpharmacological interventions, such as cognitive-behavioral therapy for insomnia, in older adults. All of the clinical trials reported herein were funded by Sepracor. This paper provides an overview of the literature on eszopiclone with special emphasis on its use for the treatment of late-life insomnia. Specific topics covered include pharmacology, pharmacodynamics, pharmacokinetics, clinical trial data, adverse events, drug interactions, tolerance/dependence, and economics/cost considerations for older adults. Keywords: aging, eszopiclone, hypnotics, insomnia, older adults, sedative-hypnoticsChristina S McCraeAmanda RossAshley StriplingNatalie D DautovichDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 2, Pp 313-326 (2007)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Christina S McCrae Amanda Ross Ashley Stripling Natalie D Dautovich Eszopiclone for late-life insomnia
description	Christina S McCrae1, Amanda Ross1, Ashley Stripling2, Natalie D Dautovich21Department of Clinical and Health Psychology, 2Department of Psychology, University of Florida, Gainesville, Florida, USAAbstract: Insomnia, the most common sleep disturbance in later life, affects 20%–50% of older adults. Eszopiclone, a short-acting nonbenzodiazepine hypnotic agent developed for the treatment of insomnia, has been available in Europe since 1992 and in the US since 2005. Although not yet evaluated for transient insomnia in older adults, eszopiclone has been shown to be safe and efficacious for short-term treatment (2 weeks) of chronic, primary insomnia in older adults (64–91 years). Clinical studies in younger adults (mean = 44 years) have shown eszopiclone can be used for 6–12 months without evidence of problems. Because the oldest participant in these longer-term trials was 69, it not known whether eszopiclone is effective for older adults [particularly the old old (75–84 years) and oldest old (85+)] when used over longer periods. This is unfortunate, because older individuals frequently suffer from chronic insomnia. Cognitive-behavioral therapy for insomnia, which effectively targets the behavioral factors that maintain chronic insomnia, represents an attractive treatment alternative or adjuvant to eszopiclone for older adults. To date, no studies have compared eszopiclone to other hypnotic medications or to nonpharmacological interventions, such as cognitive-behavioral therapy for insomnia, in older adults. All of the clinical trials reported herein were funded by Sepracor. This paper provides an overview of the literature on eszopiclone with special emphasis on its use for the treatment of late-life insomnia. Specific topics covered include pharmacology, pharmacodynamics, pharmacokinetics, clinical trial data, adverse events, drug interactions, tolerance/dependence, and economics/cost considerations for older adults. Keywords: aging, eszopiclone, hypnotics, insomnia, older adults, sedative-hypnotics
format	article
author	Christina S McCrae Amanda Ross Ashley Stripling Natalie D Dautovich
author_facet	Christina S McCrae Amanda Ross Ashley Stripling Natalie D Dautovich
author_sort	Christina S McCrae
title	Eszopiclone for late-life insomnia
title_short	Eszopiclone for late-life insomnia
title_full	Eszopiclone for late-life insomnia
title_fullStr	Eszopiclone for late-life insomnia
title_full_unstemmed	Eszopiclone for late-life insomnia
title_sort	eszopiclone for late-life insomnia
publisher	Dove Medical Press
publishDate	2007
url	https://doaj.org/article/5302fce03c1e4fbea622ff129aaeed61
work_keys_str_mv	AT christinasmccrae eszopicloneforlatelifeinsomnia AT amandaross eszopicloneforlatelifeinsomnia AT ashleystripling eszopicloneforlatelifeinsomnia AT natalieddautovich eszopicloneforlatelifeinsomnia
_version_	1718400589491077120

Eszopiclone for late-life insomnia

Ejemplares similares